Opportunity Information: Apply for RFA DK 22 009
The Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) funding opportunity (RFA-DK-22-009) is an NIH cooperative agreement (U01) focused on accelerating research strategies that can increase, restore, or preserve functional human beta cell mass for people living with Type 1 Diabetes (T1D). The central scientific goal is to tackle one of the core problems in T1D: the loss and ongoing vulnerability of insulin-producing beta cells. This FOA is designed to support a coordinated consortium effort, meaning NIH expects funded teams to collaborate closely with NIH program staff and with other network components rather than operate as isolated, single-lab projects. Clinical trials are not allowed under this announcement, so the work is expected to stay in preclinical, translational, and mechanistic research spaces rather than testing interventions in human trial settings.
The research scope emphasizes innovative and controllable approaches to either expand beta cell numbers or protect remaining beta cells from immune-mediated destruction. The FOA highlights several main scientific paths: stimulating or controlling beta cell replication (encouraging existing beta cells to divide safely and effectively), leveraging islet cell plasticity (pushing endocrine cells within islets to shift identity or function in a beneficial way), and reprogramming pancreatic non-beta cells into beta-like cells (converting other pancreatic cell types into insulin-producing cells or cells that behave similarly). In parallel, the announcement explicitly includes strategies aimed at shielding residual beta cell mass from the autoimmune environment, reflecting the reality that even if beta cells can be regenerated, they may remain susceptible to the same immune attack that caused the disease in the first place. Overall, CTAR sits at the intersection of beta cell biology, regenerative medicine, islet biology, and immune protection strategies, with an emphasis on approaches that are mechanistically grounded and plausibly translatable to future therapies.
CTAR is part of the broader Human Islet Research Network (HIRN), which is an NIH-supported collaborative framework centered on human islet biology and diabetes. Being part of HIRN implies that CTAR projects are expected to contribute to shared consortium goals, potentially including coordinated data generation, use of common resources, harmonized methods, and active participation in network meetings and collaborative activities. Because this is a cooperative agreement mechanism, NIH typically plays an active role in shaping consortium coordination, milestone tracking, and integration across funded groups, with the intent of speeding progress through organized teamwork and shared infrastructure.
Eligibility is broad and includes many common U.S. applicant organization types such as public and private institutions of higher education, nonprofit organizations (both with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and a wide range of government entities (state, county, city/township, special district governments, independent school districts, and federally recognized tribal governments). The FOA also explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and eligible federal agencies. U.S. territories or possessions are included as eligible. At the same time, the FOA draws clear lines around foreign involvement: non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement, which typically means a U.S.-based applicant can include certain well-justified international collaborations or activities as part of the project, subject to NIH rules and approval.
From an administrative standpoint, the opportunity is categorized under discretionary funding, uses the cooperative agreement instrument (U01), and is associated with the National Institutes of Health. The activity category is listed under Food and Nutrition, Health, and the CFDA number provided is 93.847. The original closing date listed is 2022-10-26, the record creation date is 2022-07-13, and the award ceiling is stated as $600,000. The announcement also lists expected awards, although the number is not specified in the provided text.Apply for RFA DK 22 009
- The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2022-07-13.
- Applicants must submit their applications by 2022-10-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $600,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): HIRN-CTAR (RFA-DK-22-009)
What is the HIRN-CTAR funding opportunity?
The Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) funding opportunity (RFA-DK-22-009) is an NIH cooperative agreement (U01) that supports research aimed at increasing, restoring, or preserving functional human beta cell mass for people living with Type 1 Diabetes (T1D).
What problem in Type 1 Diabetes is this FOA trying to address?
The central scientific goal is to address the loss and ongoing vulnerability of insulin-producing beta cells, which is a core challenge in T1D. Projects are expected to focus on ways to regenerate beta cells and/or protect remaining beta cells from autoimmune attack.
What funding mechanism is used (grant type)?
This opportunity uses the NIH cooperative agreement mechanism U01, meaning NIH program staff are expected to have an active role in coordinating and integrating the funded work across the consortium.
What does it mean that this is a cooperative agreement (U01)?
A cooperative agreement implies more involvement from NIH compared to many traditional research grants. Funded teams are expected to collaborate closely with NIH program staff and with other network components, follow coordinated consortium expectations, and participate in milestone tracking and integration efforts.
Is this opportunity meant for single-lab projects or collaborative teams?
This FOA is designed to support a coordinated consortium effort. NIH expects funded teams to work collaboratively within the network rather than operate as isolated, single-lab projects.
Are clinical trials allowed under this announcement?
No. Clinical trials are not allowed under this FOA. The supported work is expected to remain in preclinical, translational, and mechanistic research areas rather than testing interventions in human clinical trial settings.
What kinds of research approaches are emphasized?
The scope emphasizes innovative and controllable strategies to expand beta cell numbers and/or protect remaining beta cells. The FOA highlights approaches including beta cell replication, islet cell plasticity, reprogramming non-beta pancreatic cells into beta-like cells, and immune-protection strategies designed to shield residual beta cell mass from autoimmune destruction.
What is meant by “stimulating or controlling beta cell replication”?
In the context of this FOA, beta cell replication refers to encouraging existing beta cells to divide in a way that is both safe and effective, with an emphasis on approaches that are controllable and mechanistically grounded.
What is meant by “islet cell plasticity” in this FOA?
Islet cell plasticity refers to strategies that encourage endocrine cells within the islets to shift identity and/or function in a beneficial way, with the goal of improving insulin-producing capacity or supporting beta cell regeneration.
What is meant by “reprogramming pancreatic non-beta cells into beta-like cells”?
This refers to converting other pancreatic cell types into insulin-producing cells or cells that behave similarly to beta cells, as a strategy to restore or increase functional beta cell mass.
Why does the FOA include immune protection strategies?
The FOA recognizes that even if beta cells are regenerated, they may still be vulnerable to the autoimmune environment that drives T1D. For that reason, strategies aimed at shielding residual beta cell mass from immune-mediated destruction are explicitly included.
How does CTAR relate to the Human Islet Research Network (HIRN)?
CTAR is part of the broader Human Islet Research Network (HIRN), an NIH-supported collaborative framework centered on human islet biology and diabetes. Being part of HIRN implies CTAR projects are expected to contribute to shared consortium goals and participate in coordinated network activities.
What kinds of consortium expectations are mentioned?
The opportunity describes expectations typical of a coordinated consortium, such as contributing to shared goals, potentially using common resources, generating coordinated data, using harmonized methods, and participating in network meetings and other collaborative activities.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and many government entities (including state, county, city/township, special district governments, independent school districts, and federally recognized tribal governments). U.S. territories or possessions are also included as eligible.
Are minority-serving institutions and community organizations included in eligibility?
Yes. The FOA explicitly notes eligible categories such as HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs. It also includes faith-based or community-based organizations among eligible applicants.
Are federal agencies eligible to apply?
Yes. The FOA indicates eligible federal agencies are included among eligible applicant types.
Can a non-U.S. (foreign) organization apply as the applicant?
No. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization under this FOA.
Can a non-domestic component of a U.S. organization apply?
No. The FOA states that non-domestic components of U.S. organizations are not eligible to apply.
Are any foreign activities or collaborations allowed at all?
Yes, foreign components are allowed as defined in the NIH Grants Policy Statement. In practical terms, this means a U.S.-based applicant may include certain justified international collaborations or activities as part of the project, subject to NIH rules and approval.
Which federal agency is associated with this opportunity?
This is an NIH funding opportunity.
What is the funding category and program classification listed?
The opportunity is categorized under discretionary funding. The activity category is listed under Food and Nutrition, Health. The CFDA number provided is 93.847.
What is the award ceiling for this opportunity?
The stated award ceiling is $600,000.
How many awards are expected?
The announcement lists that awards are expected, but the number of expected awards is not specified in the provided information.
What was the closing date for the original announcement record?
The original closing date listed is 2022-10-26.
When was this opportunity record created?
The record creation date listed is 2022-07-13.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)
Previous opportunity: Somatic Mosaicism across Human Tissues (SMaHT) Program: Genome Characterization Centers (UM1 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 22 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 22 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed) Apply for RFA DK 22 016 Funding Number: RFA DK 22 016 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $3,750,000 |
| Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed) Apply for RFA DK 21 031 Funding Number: RFA DK 21 031 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $700,000 |
| Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Clinical Centers (U01 - Clinical Trial Not Allowed) Apply for RFA DK 22 502 Funding Number: RFA DK 22 502 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $200,000 |
| Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Scientific and Data Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA DK 22 503 Funding Number: RFA DK 22 503 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $650,000 |
| Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed) Apply for RFA DK 22 019 Funding Number: RFA DK 22 019 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Helping to Accelerate Research Potential (HARP) (UE5 - Clinical Trial Not Allowed) Apply for RFA DK 22 002 Funding Number: RFA DK 22 002 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $150,000 |
| Integrated Physiology of Exocrine and Endocrine Pancreas in Type 1 Diabetes (R01 - Clinical Trial Not Allowed) Apply for RFA DK 22 022 Funding Number: RFA DK 22 022 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers (Collaborative U01 - Clinical Trial Not Allowed) Apply for RFA DK 22 506 Funding Number: RFA DK 22 506 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional) Apply for RFA DK 22 013 Funding Number: RFA DK 22 013 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,800,000 |
| Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 - Clinical Trial Not Allowed) Apply for RFA DK 22 508 Funding Number: RFA DK 22 508 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the APOL1 Long-term Kidney Transplantation Outcomes Network Scientific and Data Research Center (APOLLO SDRC) (Collaborative U01 - Clinical Trial Not Allowed) Apply for RFA DK 22 507 Funding Number: RFA DK 22 507 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required) Apply for RFA DK 22 020 Funding Number: RFA DK 22 020 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional) Apply for PAR 22 129 Funding Number: PAR 22 129 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $75,000 |
| Human Islet Research Network (HIRN) Pancreas Knowledgebase Program (PanKbase) (U24 - Clinical Trial Not Allowed) Apply for RFA DK 22 018 Funding Number: RFA DK 22 018 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) Apply for RFA DK 22 039 Funding Number: RFA DK 22 039 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) Apply for RFA DK 22 027 Funding Number: RFA DK 22 027 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Information Network Coordinating Unit: dkNET-CU (U24 Clinical Trial Not Allowed) Apply for RFA DK 22 017 Funding Number: RFA DK 22 017 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds (K26 - Independent Clinical Trial Not Allowed) Apply for RFA DK 22 012 Funding Number: RFA DK 22 012 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed) Apply for RFA DK 22 023 Funding Number: RFA DK 22 023 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $300,000 |
| Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required) Apply for RFA DK 22 028 Funding Number: RFA DK 22 028 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 22 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.